Format

Send to

Choose Destination
Neuropharmacology. 2015 Jan;88:48-54. doi: 10.1016/j.neuropharm.2014.06.028. Epub 2014 Jul 10.

Insights into GABAAergic system deficits in fragile X syndrome lead to clinical trials.

Author information

1
Department of Medical Genetics, University of Antwerp, Prins Boudewijnlaan 43, 2650 Edegem, Antwerp, Belgium. Electronic address: sien.braat@uantwerpen.be.
2
Department of Medical Genetics, University of Antwerp, Prins Boudewijnlaan 43, 2650 Edegem, Antwerp, Belgium. Electronic address: frank.kooy@uantwerpen.be.

Abstract

An increasing number of studies implicate the GABAAergic system in the pathophysiology of the fragile X syndrome, a frequent cause of intellectual disability and autism. Animal models have proven invaluable in unravelling the molecular mechanisms underlying the disorder. Multiple defects in this inhibitory system have been identified in Fmr1 knockout mice, including altered expression of various components, aberrant GABAA receptor-mediated signalling, altered GABA concentrations and anatomical defects in GABAergic neurons. Aberrations compatible with those described in the mouse model were detected in dfmr1 deficient Drosophila melanogaster, a validated fly model for the fragile X syndrome. Treatment with drugs that ameliorate the GABAAergic deficiency in both animal models have demonstrated that the GABAA receptor is a promising target for the treatment of fragile X patients. Based on these preclinical studies, clinical trials in patients have been initiated.

KEYWORDS:

Fragile X syndrome; GABA(A) receptor; Gaboxadol; Ganaxolone; Targeted treatment

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center